Back to All Combinations

RET Fusion + Any

Intermediate Prognosis
0.30% Prevalence B General
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
RET Fusion
Recommended Treatments
Selpercatinib
Pralsetinib
Treatments to Avoid

No specific contraindications noted

Key Statistics
0.30%
Prevalence in CRC
Yes
Targetable
Clinical Notes
Rare but actionable with selective RET inhibitors.
Information

Category: General

Evidence Level: B

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.